A surreal illustration of a brain intertwined with roots and glowing cytokines, representing the connection between TNFAIP3, inflammation, and mental health.

Anxiety and Inflammation: New Research Links TNFAIP3 Gene to Mental Health

Nico Varela monogram
Nico Varela in Health & Wellness October 2026 • 4 min read.

"Could a specific gene expression be the key to understanding the connection between psychological anxiety and major depressive disorder?"


The intricate relationship between mental health and physical well-being has long been a subject of intense scientific scrutiny. Major Depressive Disorder (MDD), characterized by persistent sadness, loss of interest, and a host of other debilitating symptoms, affects millions worldwide. While its causes are multifaceted, a growing body of evidence points to the role of inflammation and immune system dysregulation in the development and progression of MDD.

Inflammation, the body's natural response to injury or infection, can sometimes become chronic and contribute to various health problems, including mental health disorders. Cytokines, small proteins that act as messengers in the immune system, are released during inflammation. Elevated levels of pro-inflammatory cytokines have been observed in individuals with MDD, suggesting a potential link between the immune system and the brain.

Now, a new study sheds light on a specific gene, TNFAIP3, and its potential role in the connection between inflammation and anxiety in individuals with MDD. The research, published in Neuroimmunomodulation, explores the relationship between TNFAIP3 mRNA levels and the severity of psychological anxiety symptoms in patients diagnosed with major depressive disorder.

AI Search Multiple angles on this topic

The Growing Burden of Anxiety and Depression

Data from the 2022 National Health Interview Survey indicate that the percentage of adults with anxiety symptoms increased from 15.6% to 18.2% and depression symptoms from 18.5% to 21.4% between 2019 and 2022. According to the CDC, 4.7% of adults age 18 and older reported regular feelings of depression in recent estimates. These conditions represent a significant and growing public health concern in the United States.

Current Treatment Approaches and Screening Challenges

Standard treatment for anxiety disorders typically involves psychotherapy, medication, or a combination of both. However, anxiety is less reported in the media than depression and suicide attempts, which reduces help-seeking behaviors among sufferers. Additionally, widely used screening tools like the Hospital Anxiety and Depression Scale (HADS) have inconsistent factor structures, with studies reporting unidimensional, two-factor, and three-factor models, complicating accurate diagnosis.

The Shifting Focus from Anxiety to Depression

Anxiety was at the forefront of medical and psychiatric attention in the United States during the 1950s and 1960s. However, since that time, depression—once considered a rare disease in the post–World War II period—has become the primary focus of mental health concern. This shift represents one of the most puzzling phenomena in the recent history of psychiatric diagnosis.

What is TNFAIP3 and Why Is It Important for Mental Health?

A surreal illustration of a brain intertwined with roots and glowing cytokines, representing the connection between TNFAIP3, inflammation, and mental health.

TNFAIP3, or TNF Alpha Induced Protein 3, is a gene that plays a crucial role in regulating the immune system. It acts as a negative regulator of the TLR-4 signaling pathway, which is involved in innate immune responses. Essentially, TNFAIP3 helps to keep the immune system in check, preventing excessive inflammation. Think of it as the body's internal peacekeeper, ensuring that immune responses don't spiral out of control.

The researchers hypothesized that the level of TNFAIP3 mRNA expression might be associated with specific symptoms of MDD. To investigate this, they conducted a study involving 91 patients diagnosed with MDD. The participants underwent thorough assessments, including the Hamilton Depression Rating Scale (HAMD-17), a widely used tool for measuring the severity of depressive symptoms.

  • Participants: 91 patients diagnosed with MDD (20 men and 71 women).
  • Assessment: Hamilton Depression Rating Scale (HAMD-17) to evaluate depressive symptoms.
  • Analysis: Multiple linear regression to assess the relationship between TNFAIP3 mRNA levels and HAMD-17 subscores.
AI Search Multiple angles on this topic

Emerging Treatments and Research Frontiers

Recent research is exploring novel therapeutic approaches for anxiety and depression. Studies indicate that psilocybin, the psychoactive component of magic mushrooms, produces rapid and sustained effects in people with chronic pain who also have anxiety and/or depression. The field continues to evolve with new research on treatment-resistant cases and alternative interventions.

Self-Criticism and Treatment Resistance

Self-criticism and experiential avoidance are significant mediators in the relationships between early maladaptive schemas and social anxiety and depression. Individuals with depression tend to be highly self-critical, frequently maintaining an internal dialogue that is harshly judgmental of themselves. This self-critical pattern can complicate treatment outcomes and contribute to chronicity of symptoms.

Anxiety vs. Depression: Key Distinctions

Anxiety and depression are frequently confused but affect individuals in different ways. While anxiety floods the brain with worry about what might go wrong, depression drains energy and meaning from present experiences. Neither condition is categorically worse than the other, but depression consistently ranks as more disabling on clinical severity scales and carries a stronger link to suicide.

The study's findings revealed a significant correlation between TNFAIP3 mRNA expression and psychological anxiety, a specific subscore on the HAMD-17. This suggests that individuals with lower levels of TNFAIP3 expression may be more prone to experiencing psychological anxiety as part of their depressive disorder. Other symptoms, such as depressed mood, insomnia, and suicidal thoughts, did not show a significant association with TNFAIP3 mRNA levels.

Future Directions: Unraveling the Connection Between Genes, Anxiety, and Depression

This research provides a valuable piece of the puzzle in understanding the complex interplay between the immune system, genetics, and mental health. While the study highlights a significant association between TNFAIP3 and psychological anxiety in MDD, further research is needed to fully elucidate the underlying mechanisms. Larger studies with more diverse populations are essential to confirm these findings and explore the potential for targeted interventions.

AI Search Multiple angles on this topic

Integrating New Understanding into Clinical Practice

The relationship between anxiety and inflammation represents a promising avenue for advancing mental health treatment. Understanding biological mechanisms like the TNFAIP3 gene's role in inflammation could lead to more targeted interventions. As research continues to bridge immunology and psychiatry, clinicians may gain new tools for addressing these conditions beyond traditional approaches.

Projecting the Global Mental Health Burden

Anxiety and depressive disorders contribute significantly to the global mental health burden, with research projecting future prevalence trends up to 2050. The COVID-19 pandemic has significantly impacted the future burden of anxiety disorders, necessitating greater attention towards young individuals, particularly women. There is an urgent need for targeted prevention and treatment strategies on a global scale, especially in high SDI regions.

Societal Factors Influencing Mental Health

Mental health conditions extend beyond the psychological domain into social, economic, and healthcare systems. The impact of events like the COVID-19 pandemic, economic crises, and geopolitical conflicts on anxiety and depression indicators demonstrates how systemic factors shape population mental health. Social support networks and access to care remain critical variables in determining mental health outcomes.

Living with Anxiety and Depression

Behind the statistics are millions of individuals whose daily lives are significantly impacted by anxiety and depression. These conditions affect not only mental well-being but also physical health, relationships, and overall quality of life. The personal burden often extends to families and communities, underscoring the importance of accessible and effective mental health support.

What TNFAIP3 expression can tell us about anxiety

The reported link is specific to psychological anxiety scores: it does not show that TNFAIP3 expression tracks MDD symptoms generally. The same source describes MDD as associated with inflammation and dysregulated innate immune responses, but that broader association does not establish what TNFAIP3 levels mean for any individual patient.[1]

How TNFAIP3 findings compare with wider inflammation research

The TNFAIP3 finding concerns a specific symptom association in patients with MDD, whereas a meta-analysis spanning many studies examined sex-specific associations between depression and inflammatory markers. That broader design addresses variation across studies and sexes, not the same gene-expression question.[1] [2]

A large cohort analysis associated higher leukocyte, haptoglobin, or CRP levels with elevated risk of psychiatric disorders. Other work notes that possible selection bias could help explain inflammation associations and that IL-6 was not measured in the UK Biobank cohort, leaving that marker unassessed there.[3] [4]

Treatment research offers a different kind of evidence: meta-analyses of clinical trials indicate anti-inflammatory drugs may have antidepressant effects. In cell-line experiments, fluoxetine increased TNFAIP3 mRNA and suppressed IL-6, with the suppression weakened when TNFAIP3 was knocked down; these experimental observations do not establish effects in patients.[5] [6]

What remains unclear about TNFAIP3 and anxiety

  • Does the association between TNFAIP3 expression and psychological anxiety hold across different cell types, given the reported contrast between lower levels in PBMC and monocytes and higher levels in TNF-α-secreting cells?[1] [7]
  • How might sex-specific patterns in depression–inflammation associations affect interpretation of TNFAIP3-related findings in MDD?[1] [2]
  • Would measuring IL-6 alongside other inflammatory markers clarify how inflammation relates to anxiety and depression in cohorts where IL-6 was not measured?[4] [8]

Sources

  1. TNFAIP3 mRNA Level Is Associated with Psychological Anxiety in Major Depressive Disorder. (pubmed.ncbi.nlm.nih.gov)
  2. Sex-specific associations of depression with inflammatory markers: a systematic review and meta-analysis (pmc.ncbi.nlm.nih.gov)
  3. Inflammatory Biomarkers and Risk of Psychiatric Disorders - PMC Lock (pmc.ncbi.nlm.nih.gov)
  4. Role of inflammation in depression and anxiety: Tests for disorder specificity, linearity and potential causality of association in the UK Biobank (pmc.ncbi.nlm.nih.gov)
  5. Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls (pmc.ncbi.nlm.nih.gov)
  6. TNFAIP3, a negative regulator of the TLR signaling pathway, is a potential predictive biomarker of response to antidepressant treatment in major depressive disorder. (pubmed.ncbi.nlm.nih.gov)
  7. SIGIRR and TNFAIP3 Are Differentially Expressed in Both PBMC and TNF-α Secreting Cells of Patients With Major Depressive Disorder (pmc.ncbi.nlm.nih.gov)
  8. Association of inflammation with depression and anxiety: evidence for symptom-specificity and potential causality from UK Biobank and NESDA cohorts (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is the role of TNFAIP3 in the body, and how does it relate to mental health?

TNFAIP3, or TNF Alpha Induced Protein 3, functions as a key regulator of the immune system. It acts as a negative regulator of the TLR-4 signaling pathway, which is crucial for innate immune responses. In essence, TNFAIP3 helps to keep the immune system in check, preventing excessive inflammation. This function is particularly relevant to mental health because chronic inflammation has been linked to the development and progression of Major Depressive Disorder (MDD). The recent research specifically links lower levels of TNFAIP3 expression to increased psychological anxiety in individuals with MDD, suggesting a potential pathway through which immune dysregulation impacts mental well-being.

2

How was the connection between TNFAIP3 and psychological anxiety in Major Depressive Disorder (MDD) established in the study?

The connection between TNFAIP3 and psychological anxiety in individuals with MDD was established through a study involving 91 patients diagnosed with MDD. These participants underwent assessments using the Hamilton Depression Rating Scale (HAMD-17), a tool used for measuring the severity of depressive symptoms. Researchers analyzed the relationship between TNFAIP3 mRNA levels and specific subscores of the HAMD-17. The study revealed a significant correlation between TNFAIP3 mRNA expression and psychological anxiety, suggesting that individuals with lower levels of TNFAIP3 expression may experience more psychological anxiety as part of their depressive disorder.

3

Besides psychological anxiety, were other symptoms of Major Depressive Disorder (MDD) also linked to TNFAIP3?

No, the study did not find a significant association between TNFAIP3 mRNA levels and other symptoms of MDD such as depressed mood, insomnia, or suicidal thoughts. The research specifically highlighted a correlation between TNFAIP3 mRNA expression and psychological anxiety, which is a specific subscore of the HAMD-17 assessment tool. This indicates that while TNFAIP3 might influence the development of anxiety in MDD patients, it does not appear to have a significant direct impact on other common symptoms associated with the disorder.

4

How might understanding the relationship between TNFAIP3 and anxiety in Major Depressive Disorder (MDD) lead to new treatments or interventions?

Understanding the relationship between TNFAIP3 and psychological anxiety in MDD could open new avenues for targeted interventions. Since TNFAIP3 helps regulate the immune system, potential treatments could focus on modulating the immune response to influence TNFAIP3 expression. This might involve the development of medications or therapies that can increase TNFAIP3 levels or enhance its function, potentially reducing psychological anxiety in individuals with MDD. Furthermore, this knowledge could help in personalizing treatments, allowing clinicians to tailor interventions based on an individual's TNFAIP3 levels and the specific symptoms they experience.

5

What are the next steps in researching the connection between TNFAIP3, anxiety, and Major Depressive Disorder (MDD)?

The next steps involve conducting larger studies with more diverse populations to confirm the findings. These studies should aim to fully elucidate the mechanisms underlying the connection between TNFAIP3, inflammation, and anxiety in MDD. Researchers may also explore the potential for targeted interventions, such as therapies that can regulate TNFAIP3 expression or modulate the immune response. Understanding the genetic and immunological pathways involved will be crucial for developing effective and personalized treatments for individuals struggling with MDD and its associated symptoms, like psychological anxiety. Further research should also investigate the specific role of the TLR-4 signaling pathway, which is regulated by TNFAIP3.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.